Developing LRP1 Agonists into a Therapeutic Strategy in Acute Myocardial Infarction
AbstractCardioprotection refers to a strategy aimed at enhancing survival pathways in the injured yet salvageable myocardium following ischemia-reperfusion. Low-density lipoprotein receptor-related protein 1 (LRP1) is a multifunctional receptor that can be targeted following reperfusion, to induce a cardioprotective signaling through the activation of the reperfusion injury salvage kinase (RISK) pathway. The data from preclinical studies with non-selective and selective LRP1 agonists are promising, showing a large therapeutic window for intervention to reduce infarct size after ischemia-reperfusion. A pilot clinical trial with plasma derived α1-antitrypsin (AAT), a naturally occurring LRP1 agonist, supports the translational value of LRP1 as a novel therapeutic target for cardioprotection. A phase I study with a selective LRP1 agonist has been completed showing no toxicity. These findings may open the way to early phase clinical studies with pharmacologic LRP1 activation in patients with acute myocardial infarction (AMI). View Full-Text
Share & Cite This Article
Potere, N.; Del Buono, M.G.; Niccoli, G.; Crea, F.; Toldo, S.; Abbate, A. Developing LRP1 Agonists into a Therapeutic Strategy in Acute Myocardial Infarction. Int. J. Mol. Sci. 2019, 20, 544.
Potere N, Del Buono MG, Niccoli G, Crea F, Toldo S, Abbate A. Developing LRP1 Agonists into a Therapeutic Strategy in Acute Myocardial Infarction. International Journal of Molecular Sciences. 2019; 20(3):544.Chicago/Turabian Style
Potere, Nicola; Del Buono, Marco G.; Niccoli, Giampaolo; Crea, Filippo; Toldo, Stefano; Abbate, Antonio. 2019. "Developing LRP1 Agonists into a Therapeutic Strategy in Acute Myocardial Infarction." Int. J. Mol. Sci. 20, no. 3: 544.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.